tildrakizumab at a glance
Medicine class
Humanised monoclonal antibody and selective IL-23 inhibitor
Licensed use
Moderate to severe plaque psoriasis in adults suitable for systemic therapy
Administration
Injection under the skin; self-injection may be possible after training and clinician agreement
Key precaution
Screen for tuberculosis and review infections and vaccination plans before treatment
What is tildrakizumab used for?
Tildrakizumab is licensed for:
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
How does tildrakizumab work?
It binds selectively to the p19 component of interleukin-23, preventing receptor activation and reducing inflammatory signalling involved in plaque psoriasis. It does not directly block interleukin-12.
tildrakizumab preparations and strengths
Injection
Route: Parenteral
Strengths: 100 mg, 200 mg
How to take tildrakizumab
Tildrakizumab is injected under the skin. Self-injection may be possible after training and clinician agreement. Follow the pack instructions and specialist plan.
Rotate injection sites and avoid affected, tender, bruised, red, hard, thick or scaly skin.
Let the syringe reach room temperature naturally; do not shake, freeze or heat it.
Do not use the solution if it is cloudy, distinctly brown or contains visible particles.
Place each single-use syringe in an appropriate sharps container after injection.
tildrakizumab side effects
Common or expected effects
- Upper respiratory tract infections, including nasopharyngitis
- Headache
- Diarrhoea or gastroenteritis
- Nausea
- Back pain
- Injection-site pain
Get urgent medical advice
- Swelling of the face, lips or throat, wheezing or difficulty breathing, which may indicate a serious allergic reaction
- Symptoms of a clinically important or serious infection
tildrakizumab in pregnancy
Human pregnancy information is limited, so avoidance during pregnancy is advised as a precaution. Discuss contraception, pregnancy planning or a positive pregnancy test with the specialist. Effective contraception is advised during treatment and for at least 17 weeks afterwards.
tildrakizumab while breastfeeding
It is unknown whether tildrakizumab enters human breast milk, and risk to a newborn—particularly during the first days after birth—cannot be excluded. The benefits of breastfeeding and treatment should be weighed before deciding whether to breastfeed or use tildrakizumab.
tildrakizumab interactions
Tell the specialist team about medicines, vaccines and light-based treatments. Conventional CYP-mediated interactions are not expected, but these require attention:
Live vaccines
Do not give concurrently; plan vaccination timing with the specialist team.
Other immunosuppressants, including biological therapies
Combination safety and effectiveness have not been evaluated, so specialist review is required.
Phototherapy
Safety and effectiveness alongside tildrakizumab have not been evaluated.
Common questions about tildrakizumab
Answers are fully visible for fast scanning and source review.
What is tildrakizumab used for?
Moderate to severe plaque psoriasis in adults suitable for systemic treatment.
Is tildrakizumab a biologic?
Yes. It is a humanised monoclonal antibody that selectively blocks IL-23.
Can I inject it myself?
Possibly, after training and when the supervising clinician agrees it is suitable.
Can I have vaccines?
Live vaccines must not be given during treatment. Check planned vaccinations with the specialist team.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.